NCT05523167

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

← Hub

Registry fields

Overall status: COMPLETED
Conditions: Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Study type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Primary purpose: TREATMENT
Intervention type: BIOLOGICAL, OTHER
Interventions: EFG PH20 SC, PBO
Lead sponsor: argenx (INDUSTRY)

Cached at: 2026-07-25 04:09:41

View on ClinicalTrials.gov

Brief summary

This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome \[ASyS\]) will be included in the study. Treatment response will be measured by Total improvement score (TIS).

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report